Grufity logo
Grufity logo
ANIX

ANIX - Anixa Biosciences Inc Stock Price, Fair Value and News

$2.64+0.16 (+6.45%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

16/100

ANIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

16/100

ANIX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANIX Price Action

Last 7 days

2.4%

Last 30 days

-10.6%

Last 90 days

-12.8%

Trailing 12 Months

-24.5%

ANIX RSI Chart

ANIX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANIX Valuation

Market Cap

89.6M

Price/Earnings (Trailing)

-8.93

Price/Sales (Trailing)

318.87

EV/EBITDA

-8.43

Price/Free Cashflow

-12.58

ANIX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANIX Fundamentals

ANIX Revenue

ANIX Earnings

Earnings (TTM)

-10.0M

Earnings Growth (Yr)

9.82%

Earnings Growth (Qtr)

1.91%

ANIX Profitability

EBT Margin

-3820.67%

Return on Equity

-75.88%

Return on Assets

-67.5%

Free Cashflow Yield

-7.95%

ANIX Investor Care

Shares Dilution (1Y)

5.31%

Diluted EPS (TTM)

-0.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025----
2024----
2023----
2022----
2021----
2020----
2019-1.4M806.3K250.0K
2018-918.8K1.5M1.1M
2017--331.3K362.5K
20167.0M4.8M2.5M300.0K
20156.5M--9.3M
20141.2M2.0M2.8M3.7M
2013---388.9K
20121.4M1.6M1.4M940.0K
2011798.8K866.9K935.1K1.0M
2010---730.7K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Anixa Biosciences Inc

ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
 CEO
 WEBSITEanixa.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES4

Anixa Biosciences Inc Frequently Asked Questions

ANIX is the stock ticker symbol of Anixa Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Anixa Biosciences Inc is 84.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, ANIX's PE ratio (Price to Earnings) is -8.38 and Price to Sales (PS) ratio is 318.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Anixa Biosciences Inc has provided -0.028 (multiply by 100 for percentage) rate of return.